CN113755370A - 嗜酸乳杆菌la85在制备降血脂药物或保健食品上的应用 - Google Patents
嗜酸乳杆菌la85在制备降血脂药物或保健食品上的应用 Download PDFInfo
- Publication number
- CN113755370A CN113755370A CN202110965484.3A CN202110965484A CN113755370A CN 113755370 A CN113755370 A CN 113755370A CN 202110965484 A CN202110965484 A CN 202110965484A CN 113755370 A CN113755370 A CN 113755370A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus acidophilus
- blood fat
- serum
- intestinal flora
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 240000001046 Lactobacillus acidophilus Species 0.000 title claims abstract description 60
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 title claims abstract description 60
- 229940039695 lactobacillus acidophilus Drugs 0.000 title claims abstract description 60
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 12
- 210000004369 blood Anatomy 0.000 title abstract description 21
- 239000008280 blood Substances 0.000 title abstract description 21
- 229940079593 drug Drugs 0.000 title abstract description 8
- 235000013305 food Nutrition 0.000 title abstract description 6
- 239000000843 powder Substances 0.000 claims abstract description 34
- 235000013402 health food Nutrition 0.000 claims abstract description 8
- 239000006041 probiotic Substances 0.000 claims abstract description 5
- 235000018291 probiotics Nutrition 0.000 claims abstract description 5
- 235000015140 cultured milk Nutrition 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 238000004321 preservation Methods 0.000 claims description 3
- 235000019985 fermented beverage Nutrition 0.000 claims description 2
- 230000000055 hyoplipidemic effect Effects 0.000 claims description 2
- 230000000529 probiotic effect Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 235000020122 reconstituted milk Nutrition 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 31
- 210000002966 serum Anatomy 0.000 abstract description 17
- 235000012000 cholesterol Nutrition 0.000 abstract description 15
- 241000699670 Mus sp. Species 0.000 abstract description 13
- 230000001580 bacterial effect Effects 0.000 abstract description 13
- 230000000968 intestinal effect Effects 0.000 abstract description 12
- 108010023302 HDL Cholesterol Proteins 0.000 abstract description 9
- 241000186660 Lactobacillus Species 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 241000186000 Bifidobacterium Species 0.000 abstract description 4
- 241000193468 Clostridium perfringens Species 0.000 abstract description 4
- 238000000338 in vitro Methods 0.000 abstract description 3
- 150000002632 lipids Chemical class 0.000 abstract description 2
- 244000005700 microbiome Species 0.000 abstract description 2
- 230000002354 daily effect Effects 0.000 abstract 1
- 230000003203 everyday effect Effects 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 description 18
- 230000004151 fermentation Effects 0.000 description 18
- 238000012360 testing method Methods 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000002068 microbial inoculum Substances 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 206010033307 Overweight Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000003223 protective agent Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000010802 sludge Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000009777 vacuum freeze-drying Methods 0.000 description 4
- 241000606125 Bacteroides Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 229940054441 o-phthalaldehyde Drugs 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 3
- 238000011218 seed culture Methods 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000588914 Enterobacter Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- 244000199885 Lactobacillus bulgaricus Species 0.000 description 2
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000194020 Streptococcus thermophilus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 235000020927 12-h fasting Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000021336 beef liver Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000010565 inoculated fermentation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 229940040511 liver extract Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/113—Acidophilus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明提供嗜酸乳杆菌LA85在制备降血脂药物或保健食品上的应用，属于微生物技术领域，通过食用益生菌代替药物，从根本上调节肠道菌群并降低血脂。嗜酸乳杆菌LA85具有较高的体外胆固醇去除率，能够显著降低高脂小鼠血清TC、TG水平，提高血清HDL‑C水平。每天食用2g（200亿CFU）嗜酸乳杆菌LA85菌粉14d后，肠道中双歧杆菌和乳杆菌均显著增加，拟杆菌、肠杆菌、肠球菌、产气荚膜梭菌均无明显变化，嗜酸乳杆菌La85菌粉具有调剂肠道菌群的功能。嗜酸乳杆菌La85可广泛应用于食品领域，通过日常摄入而不需要通过药物达到调节肠道菌群、降低血脂的目的。
Description
技术领域
本发明属于微生物技术领域，尤其是涉及嗜酸乳杆菌LA85在制备降血脂药物或保健食品上的应用。
背景技术
《中国居民营养与慢性病状况报告(2020年)》中指出城乡各年龄段居民超重肥胖率继续上升，有超过50％的成年居民超重肥胖，18岁及以上居民超重率和肥胖率分别为34.3％和16.4％。6～17岁、6岁以下儿童青少年超重肥胖率分别达到19％和10.4％。而且呈现出上升速度较快、流行水平较高、全人群均受影响的发展趋势。而高血脂症是超重肥胖常见的相关并发症。高血脂症通常会引起内皮细胞的功能障碍以及血管壁功能和结构的损伤，并直接引起动脉粥样硬化、冠心病及胰腺炎等一些严重危害人体健康的疾病。常用的药物治疗主要是将血脂长期控制在一定范围，并没有完全治愈高血脂症，最常用的降脂药有他汀类药物、氯贝丁酯类、烟酸类及胆酸鳌合树脂类等。随着国人健康意识提高，越来越多的人倾向于通过改善饮食、食用益生菌等方式代替药物治疗来实现身体的健康。嗜酸乳杆菌是常见益生菌之一，本发明所述嗜酸乳杆菌LA85通过调节肠道菌群降低血脂，实现降低高血脂的目的。
发明内容
本发明提供嗜酸乳杆菌LA85在制备降血脂药物或保健食品上的应用。高血脂症患者通过食用含有益生菌LA85的药物或保健食品代替化学药物，可以从根本上调节肠道菌群并降低血脂。
本发明涉及的嗜酸乳杆菌LA85，其分类命名为嗜酸乳杆菌Lactobacillusacidophilus，该菌株于2021年02月01日保藏于中国微生物菌种保藏管理委员会普通微生物中心(CGMCC)，地址为北京市朝阳区北辰西路1号院3号，保藏编号为CGMCC No.21802。其首次公开在中国专利申请202110285880.1中。
本发明的体外实验证明，本发明所述的嗜酸乳杆菌LA85，具有较高的体外胆固醇去除率。所述的嗜酸乳杆菌LA85，能够显著降低高脂小鼠血清TC、TG水平，提高血清HDL-C水平。
所述的嗜酸乳杆菌LA85菌剂，人体试食15天后，与食用前及对照组相比，双歧杆菌和乳杆菌均显著增加，拟杆菌、肠杆菌、肠球菌、产气荚膜梭菌均无明显变化。可见，嗜酸乳杆菌LA85菌剂具有调剂肠道菌群的功能。
所述的嗜酸乳杆菌LA85菌粉发酵工艺：将保存于甘油管中的嗜酸乳杆菌菌株经过两级活化，接种到发酵罐中发酵。在发酵温度为35℃、搅拌转速100rpm、初始pH调节为6.5的条件下开始发酵，发酵过程中用23％(m/v)碳酸钠维持pH为5.8，维持罐压为0.03MPa，培养10h。
所述的嗜酸乳杆菌LA85菌粉制备工艺：
(1)将通过上述嗜酸乳杆菌发酵液4℃、8000rpm离心10min，去上清，收集菌泥。
(2)按照菌泥与冻干保护剂质量比1:1-1.2将两者混合均匀，进行真空冷冻干燥得到嗜酸乳杆菌冻干菌粉。所述的真空冷冻干燥的条件为：预冻温度为-42～-45℃，真空度10-20pa，时间24-28h。
所述的冻干保护剂包含如下按质量百分比计的组分：15％海藻糖，5％脱脂奶粉，2％蔗糖，2％甘油，0.5％山梨醇。
本发明提供了嗜酸乳杆菌LA85在制备降血脂保健食品上的应用。
所述保健食品，包括压片糖果、发酵饮料、软糖、调制乳粉、发酵乳、固体饮料。
本发明还提供了嗜酸乳杆菌LA85在制备降血脂药物上的应用，所述药物包括但不限于微生态制剂。
本发明所采用的嗜酸乳杆菌LA85来自健康人体肠道，安全无致病性，通过体外试验、小鼠试验、人体试食试验证明其具有调节肠道菌群、降血脂功效。将其广泛应用到食品领域，增大消费者摄入的可能性，通过日常摄入就可以达到调节肠道菌群、降低血脂的目的。当然，所采用的嗜酸乳杆菌LA85也可以用于制备降低血脂的药物中。
具体实施方式
以下由特定的具体实施例说明本发明的实施方式，熟悉此技术的人士可由本说明书所揭露的内容轻易地了解本发明的其他优点及功效。
以下实施例用于说明本发明，但不用来限制本发明的范围。
实施例1嗜酸乳杆菌胆固醇去除率测定
菌株活化：从-80℃冰箱取出甘油管，解冻后，以2％接种量接种于装有MRS培养基的厌氧管中，置于37℃培养12h-24h，生长至菌液浑浊为活化一代。
MRS培养基成分：蛋白胨10g、牛肉浸粉5g、酵母浸粉4g、K2HPO4 2g、柠檬酸三铵2g、乙酸钠5g、葡萄糖20g、吐温80 1mL、MgSO4·7H2O 0.58g、MnSO4·4H2O 0.25g、蒸馏水1000mL；pH值6.2±0.2；培养条件：37℃，静置培养：18-24h。
(1)胆固醇标准曲线测定：准确称取0.1g胆固醇粉末，正己烷定容1mg/mL的溶液，然后分别吸取0.02、0.04、0.06、0.08、0.1、0.12、0.14mL到比色管中，60℃水浴氮气吹干后，加入4mL 0.5mg/mL邻苯二甲醛溶液和2mL 98％浓硫酸，显色反应20min，在553nm处测定吸光度值，以胆固醇含量为横轴，吸光度值为纵轴作标准曲线。
(2)邻苯二甲醛测定胆固醇含量的方法：取1mL样品，加入3mL 95％乙醇和2mL50％(w/v)氢氧化钾，涡旋振荡混匀。于60℃下恒温水浴10min，冷却后加入5mL正己烷，涡旋震荡萃取1-2min，加入2mL蒸馏水，振荡均匀，静置分层。取2mL上层正己烷，60℃水浴氮气吹干，加入4mL 0.5mg/mL(w/v)邻家二甲醛溶液(用冰醋酸定容)和2mL浓硫酸显色反应20min，在553nm处测定吸光度值。
(3)嗜酸乳杆菌胆固醇去除率测定：
将菌种接种于装有MRS液体培养基的厌氧管中，37℃静置培养12h转接3次活化后，按2％(v/v)接种量接种于5mL培养液MRSO-CHOL中，摇匀后立即取样1mL，4000r/min离心5min，取上清液用邻苯二甲醛比色法测定胆固醇含量。接种后的发酵液37℃静置培养12h、18h、24h后用同样方法测定上清中胆固醇含量，做多组平行求平均值。其中培养液MRSO-CHOL的组成：由MRS液体培养基、巯基乙酸钠、胆固醇和牛胆盐组成；巯基乙酸钠的浓度为2g/L，胆固醇的浓度为200mg/L，牛胆盐的浓度为0.3％(质量分数)，115℃灭菌20min。
胆固醇的去除率：
式中：A为菌株发酵后的培养基553nm处的吸光度值，B为空白对照553nm处的吸光度值。
(4)嗜酸乳杆菌胆固醇去除率
表1嗜酸乳杆菌胆固醇去除率结果
实施例2嗜酸乳杆菌LA85降血脂能力评估
(1)实验分组及喂养方式
取培养后的嗜酸乳杆菌LA85，用生理盐水洗涤3次，将浓度调整至1.0×109CFU/mL用于小鼠灌胃试验。将40只8周龄BALB/c小鼠按各组间平均体质量无显著差异重新分为2组：正常组：饲喂基础饲料，对照组：饲喂高脂饲料+生理盐水，实验组：饲喂高脂饲料+嗜酸乳杆菌LA85，每组20只。每只小鼠灌胃1mL/次，连续灌胃14d。
(2)血清中血清胆固醇(TC)、血清甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)含量的测定
在小鼠灌胃14d禁食12h，分别采血，2500r/min离心10min，取血清。分别参照试剂盒说明，采用酶标仪测定血清中TC、TG和HDL-C的含量并对比各组间血清指标的差异。
(3)数据处理
采用SPSS 26统计软件，用方差分析检验显著性，多重比较用最小显著性差异法(least significant difference，LSD)检验进行数据分析。
(4)嗜酸乳杆菌LA85对高血脂症小鼠的影响
表2嗜酸乳杆菌LA85对小鼠血清TC、TG、HDL-C的影响(mmol/L)
注：同一列不同字母表示差异显著(P＜0.05)。
由表2可知，小鼠饲喂高脂饲料14天，实验小组小鼠血清TC水平显著低于对照组，与正常组小鼠的血清TC水平无显著性差异，说明饲喂嗜酸乳杆菌LA85可显著降低高脂小鼠的血清TC水平，降低后的效果接近正常组小鼠；实验组小鼠血清TG含量显著低于对照组，且显著高于正常组小鼠血清TG含量，说明饲喂嗜酸乳杆菌LA85可显著降低高脂小鼠的血清TG水平；实验组小鼠血清HDL-C含量与正常组无显著性差异，显著高于对照组，说明饲喂嗜酸乳杆菌LA85可降低高脂小鼠的血清HDL-C水平。饲喂嗜酸乳杆菌LA85能够显著降低高脂小鼠血清TC、TG水平，提高HDL-C水平，参照《保健食品检验与评价技术规范》可判定嗜酸乳杆菌LA85具有降血脂功能。
实施例3人体试食试验
1)受试者招募标准：(1)一个月内未患过胃肠疾病；(2)一个月内未服用过抗生素；(3)短期内未服用过与受试功能相关的物品(4)65岁以下年龄，非妊娠或哺乳期妇女。
2)实验方法：将符合标准的受试者随机分为对照组和试食组，每组50人，试食组每日服用2次嗜酸乳杆菌LA85菌剂，每次1克(含100亿CUF)；对照组每日服用等量的淀粉，连续服用14天，试验期间不改变原来的饮食习惯。无菌采取受试者服用前后的粪便1.0g。10倍系列稀释，选择合适的稀释度分别接种在各培养基上，计数菌落，计算出每克湿便中的菌数。各种肠道菌群的培养基及培养条件见表3。
表3肠道菌群培养条件及培养基
3)结果处理：试验数据为计量资料，采用t检验进行分析。自身对照资料采用配对t检验，两组均数比较采用成组t检验分析。
4)人体试食结果及分析
表4人体试食前后肠道菌群变化(Lg cfu/g)
注：大写字母为试食后与对照组相比，P＜0.05；小写字母为试食组与试食前相比，P＜0.05。
从表4中可以看出试食后试食组与对照组相比，双歧杆菌和乳杆菌显著增加，拟杆菌、肠杆菌、肠球菌、产气荚膜梭菌无明显变化；试食嗜酸乳杆菌LA85菌剂后与试食前比双歧杆菌和乳杆菌显著增加，拟杆菌、肠杆菌、肠球菌、产气荚膜梭菌无明显变化。可见，嗜酸乳杆菌LA85菌剂具有调剂肠道菌群的功能。
实施例3嗜酸乳杆菌LA85菌粉制备
1)嗜酸乳杆菌LA85菌粉发酵工艺：
将保存于甘油管中的嗜酸乳杆菌菌株接入10mL种子培养基中，37℃静置培养6-8h即为一级种子；
将一级种子以5％的接种量接种于200mL种子培养基中，37℃静置培养5-6h即为二级种子；
发酵罐培养：发酵罐体积为15L，装入发酵培养基10L，灭菌温度为115℃，20min，以2％(v/v)的接种量将培养获得的二级种子全部接种到发酵罐，在发酵温度为35℃、搅拌转速100rpm、初始pH调节为6.5的条件下开始发酵，发酵过程中用23％(m/v)碳酸钠维持pH为5.8，维持罐压为0.03MPa，培养10h。
所述的种子培养基的配方为：20g/L葡萄糖，10g/L牛肉浸粉，5g/L酵母粉，10g/L蛋白胨，5g/L乙酸钠，2g/L柠檬酸钠，3g/L磷酸氢二钾，0.5g/L酸镁，0.1g/L硫酸锰，1g/L吐温80，1g/L L-半光氨酸盐酸盐，115℃灭菌20min。
所述发酵培养基配方为：50g/L乳糖，15g/L酵母粉，20g/L蛋白胨，5g/L牛肝浸粉，5g/L乙酸钠，3g/L柠檬酸钠，3g/L磷酸氢二钾，0.5g/L硫酸镁，0.1g/L硫酸锰，1g/L吐温80，1g/L L-半光氨酸盐酸盐，115℃灭菌20min。
2)所述的嗜酸乳杆菌LA85菌粉制备工艺：
(1)将通过上述嗜酸乳杆菌高密度发酵的方法得到的发酵液离心，去上清，收集菌泥。所述的离心的方法优选为4℃、8000rpm离心10min。
(2)按照菌泥与冻干保护剂质量比1:1-1.2将两者混合均匀，进行真空冷冻干燥得到嗜酸乳杆菌冻干菌粉。所述的真空冷冻干燥的条件为：预冻温度为-42～-45℃，真空度10-20pa，时间24-28h。
所述的冻干保护剂包含如下按质量百分比计的组分：15％海藻糖，5％脱脂奶粉，2％蔗糖，2％甘油，0.5％山梨醇。
实施例4嗜酸乳杆菌在调制乳粉中的应用
1)调制乳粉原料配比
2)调制乳粉的干法制备工艺：
(1)称量：按照配比称量所有原料；
(2)预混：将嗜酸乳杆菌粉剂与菊粉预混3-5分钟，过40目的筛；
(3)总混：将所有原料总混20-50分钟，得到具有调节肠道、降低血脂的调制乳粉组合物。
3)调制乳粉湿法工艺：
去除鲜牛乳中的杂质并标准化；将脱脂乳粉、木糖醇、菊粉、低聚木糖搅拌溶解15分钟，水合25分种，打入生牛乳中；16-18Mpa/65℃条件下均质；杀菌温度88-92℃，浓缩至浓度13Be；高压泵压力14-17MPa，进风温度170-190℃，排风温度80-84℃，进行喷雾干燥，得到干粉A；将嗜酸乳杆菌菌粉与部分干粉A预混3-5分钟，过40目的筛得到B；将B、和其余干粉A总混20-50分钟，得到具有调节肠道、降低血脂的调制乳粉组合物。
实施例5嗜酸乳杆菌在发酵乳中的应用
原料重量份(每1000mL)：白砂糖80克；增稠剂5克；嗜酸乳杆菌LA85菌粉1克、嗜热链球菌/保加利亚乳杆菌发酵剂0.04活力单位，鲜牛奶定容至1000mL。
发酵乳的制备工艺：
(1)将稳定剂、白砂糖混匀后加入加热的鲜牛奶中，搅拌溶解均匀后得到混合料；
(2)将所述混合料均质、杀菌和冷却，获得冷却后的基料；其中均质压150～170bar，杀菌温度：95±3℃、时间300秒，冷却至42±1℃。
(3)向所述基料接种所述嗜酸乳杆菌LA85菌粉、嗜热链球菌/保加利亚乳杆菌发酵剂，43℃静置发酵10h，即获得具有调节肠道、降低血脂功能的酸奶。
Claims (4)
1.嗜酸乳杆菌LA85在制备降血脂保健食品上的应用，所述嗜酸乳杆菌LA85保藏编号为CGMCC No.21802。
2.根据权利要求1所述的应用，其特征在于，所述保健食品包括压片糖果、发酵饮料、软糖、调制乳粉、发酵乳或固体饮料。
3.嗜酸乳杆菌LA85在制备降血脂药物上的应用，所述嗜酸乳杆菌LA85保藏编号为CGMCC No.21802。
4.根据权利要求3所述的应用，其特征在于，所述药物包括微生态制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110965484.3A CN113755370B (zh) | 2021-08-23 | 2021-08-23 | 嗜酸乳杆菌la85在制备降血脂药物或保健食品上的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110965484.3A CN113755370B (zh) | 2021-08-23 | 2021-08-23 | 嗜酸乳杆菌la85在制备降血脂药物或保健食品上的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113755370A true CN113755370A (zh) | 2021-12-07 |
| CN113755370B CN113755370B (zh) | 2023-11-14 |
Family
ID=78790760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110965484.3A Active CN113755370B (zh) | 2021-08-23 | 2021-08-23 | 嗜酸乳杆菌la85在制备降血脂药物或保健食品上的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113755370B (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114686407A (zh) * | 2022-05-13 | 2022-07-01 | 微康益生菌(苏州)股份有限公司 | 一种提高可培养细胞含量的嗜酸乳杆菌菌粉的制备方法 |
| CN116515684A (zh) * | 2023-03-29 | 2023-08-01 | 微康益生菌(苏州)股份有限公司 | 一种改善高磷血症的益生菌剂及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62258323A (ja) * | 1986-05-02 | 1987-11-10 | Snow Brand Milk Prod Co Ltd | 血清コレステロ−ル上昇抑制剤 |
| CN101139558A (zh) * | 2006-09-07 | 2008-03-12 | 内蒙古农业大学 | 一种嗜酸乳杆菌及其在改善血脂代谢和免疫调节中的应用 |
| WO2018112741A1 (zh) * | 2016-12-20 | 2018-06-28 | 深圳华大基因研究院 | 一种嗜酸乳杆菌及其培养方法和应用 |
| CN109182207A (zh) * | 2018-10-10 | 2019-01-11 | 北京首佳利华科技有限公司 | 一株具有调节血糖和胆固醇水平等益生功能的嗜酸乳杆菌La-SJLH001及其应用 |
| CN112662581A (zh) * | 2020-12-10 | 2021-04-16 | 天津科技大学 | 一株产具有抗肿瘤和降糖降脂活性的胞外多糖的嗜酸乳杆菌及其应用 |
| CN113088463A (zh) * | 2021-03-17 | 2021-07-09 | 武汉微康益生菌研究院有限公司 | 一种具有益生特性的嗜酸乳杆菌及其应用 |
-
2021
- 2021-08-23 CN CN202110965484.3A patent/CN113755370B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS62258323A (ja) * | 1986-05-02 | 1987-11-10 | Snow Brand Milk Prod Co Ltd | 血清コレステロ−ル上昇抑制剤 |
| CN101139558A (zh) * | 2006-09-07 | 2008-03-12 | 内蒙古农业大学 | 一种嗜酸乳杆菌及其在改善血脂代谢和免疫调节中的应用 |
| WO2018112741A1 (zh) * | 2016-12-20 | 2018-06-28 | 深圳华大基因研究院 | 一种嗜酸乳杆菌及其培养方法和应用 |
| CN109182207A (zh) * | 2018-10-10 | 2019-01-11 | 北京首佳利华科技有限公司 | 一株具有调节血糖和胆固醇水平等益生功能的嗜酸乳杆菌La-SJLH001及其应用 |
| CN112662581A (zh) * | 2020-12-10 | 2021-04-16 | 天津科技大学 | 一株产具有抗肿瘤和降糖降脂活性的胞外多糖的嗜酸乳杆菌及其应用 |
| CN113088463A (zh) * | 2021-03-17 | 2021-07-09 | 武汉微康益生菌研究院有限公司 | 一种具有益生特性的嗜酸乳杆菌及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| M SONG等: "Effect of Lactobacillus acidophilus NS1 on plasma cholesterol levels in diet-induced obese mice", 《J DAIRY SCI . 》 * |
| 张雅茹等: "一株从青海酸奶中分离出来的嗜酸乳杆菌的分离鉴定与特性研究", 《农产品加工》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114686407A (zh) * | 2022-05-13 | 2022-07-01 | 微康益生菌(苏州)股份有限公司 | 一种提高可培养细胞含量的嗜酸乳杆菌菌粉的制备方法 |
| CN114686407B (zh) * | 2022-05-13 | 2022-09-06 | 微康益生菌(苏州)股份有限公司 | 一种提高可培养细胞含量的嗜酸乳杆菌菌粉的制备方法 |
| CN116515684A (zh) * | 2023-03-29 | 2023-08-01 | 微康益生菌(苏州)股份有限公司 | 一种改善高磷血症的益生菌剂及其应用 |
| CN116515684B (zh) * | 2023-03-29 | 2024-03-01 | 微康益生菌(苏州)股份有限公司 | 一种改善高磷血症的益生菌剂及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113755370B (zh) | 2023-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3114471A1 (en) | Strain for preventing and treating metabolic diseases and use thereof | |
| CN105146614A (zh) | 一种功能性钙果酵素、酵素饮料及其生产方法 | |
| CN113832058A (zh) | 乳双歧杆菌BLa80在制备降血脂和调节肠道菌群的药物或食品中的应用 | |
| CN112056399A (zh) | 一种增强免疫力的益生菌组合物及其应用 | |
| CN108777998B (zh) | 一种调节人体肠道功能的复合益生元及其应用 | |
| CN111705012B (zh) | 一种具有促进消化作用的副干酪乳杆菌lc-37及应用 | |
| CN113755370B (zh) | 嗜酸乳杆菌la85在制备降血脂药物或保健食品上的应用 | |
| CN114921363A (zh) | 一种抑制脂肪积累的复合益生菌及其应用 | |
| KR20040027180A (ko) | 비만 또는 당뇨병의 예방 및 치료 효과를 갖는 유산균발효 유제품 및 그 제조방법 | |
| CN108795823B (zh) | 一种改善女性孕产妇肠道菌群的益生菌的培养方法和应用 | |
| CN114214230A (zh) | 一株具有共聚幽门螺杆菌能力的北酸乳杆菌及其应用 | |
| CN113355375B (zh) | 副干酪乳杆菌k56发酵合成b族维生素的方法及应用 | |
| CN116769654B (zh) | 一株动物双歧杆菌乳亚种及其应用 | |
| CN111990647A (zh) | 一种膳食纤维组合物、酸奶及其制备方法 | |
| TWI719549B (zh) | 促進嗜黏蛋白艾克曼菌生長之益生質組合物 | |
| CN117044935A (zh) | 一种具有降尿酸功能的营养组合物配方及其制备方法 | |
| CN114686405B (zh) | 一株具有减少脂肪和缓解高血糖，调节肠道免疫力的两歧双歧杆菌及其应用 | |
| CN101297820A (zh) | 屎链球菌功能信号分子制剂及其降脂减肥制品 | |
| CN113355374B (zh) | 副干酪乳杆菌et-22发酵合成b族维生素的方法及应用 | |
| CN113122471A (zh) | 一株高利用低聚半乳糖的假小链双歧杆菌及其应用 | |
| TW202202160A (zh) | 促進排便的組成物及其應用 | |
| CN110876475A (zh) | 一种药食同源组合发酵物及其制备方法 | |
| CN109662228A (zh) | 一种具有保健功能的益生菌固体饮料及其制备方法 | |
| CN115466687B (zh) | 一种降低体脂含量和体重的组合物及其应用 | |
| JP4065360B2 (ja) | コレステロール低下剤及び飲食品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |